Beijing SL Pharmaceutical Co., Ltd. (SHE:002038)

Market Cap	7.02B +3.2%
Revenue (ttm)	623.64M -5.6%
Net Income	-347.20M
EPS	-0.34
Shares Out	1.03B
PE Ratio	n/a
Forward PE	n/a
Dividend	0.02 (0.29%)
Ex-Dividend Date	Jul 4, 2025

Volume	50,995,352
Average Volume	117,000,682
Open	7.12
Previous Close	6.83
Day's Range	6.63 - 7.12
52-Week Range	5.47 - 9.40
Beta	0.10
RSI	42.68
Earnings Date	Apr 29, 2026

About Beijing SL Pharmaceutical

Beijing SL Pharmaceutical Co., Ltd., a biopharmaceutical company, research, development, and production of genetic engineering and related drugs People’s Republic of China and internationally. The company’s finished formulations include temozolomide; arsenic trioxide; lenalidomide capsules; pegylated human granulocyte-stimulating factor injection; human granulocyte-cell stimulating factor injection; recombinant human basic fibroblast growth factor for external use recombinant human basic fibroblast growth factor gel; human interleukin-11; arsen...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1994
• Employees: 889
• Stock Exchange: Shenzhen Stock Exchange
• Ticker Symbol: 002038

Financial Performance

In 2025, Beijing SL Pharmaceutical's revenue was 623.64 million, a decrease of -5.57% compared to the previous year's 660.42 million. Losses were -347.20 million, 368.8% more than in 2024.